Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aliskiren 300 mg once daily with light meal versus fasted in hypertension
2011-005297-36Phase 4Completed
- Sponsor
- Novartis
- Start
- Dec 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of aliskiren in essential hypertension (2 arms), sponsored by Novartis. Primary endpoint: 24-hour mean systolic ambulatory blood pressure change from baseline to Week 8. Started Dec 2011; status: completed.
02
Drugs
aliskiren
03
Conditions
essential hypertension
Beyond the preview
Go deeper on 2011-005297-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-005297-36.